In Bujumbura, Burundi, a year-long examination of men undergoing prostate surgery for what appeared to be benign disease revealed that nearly half harbored undetected cancers — most of them aggressive — discovered only when surgical tissue reached the pathologist. The finding speaks to a quiet crisis in places where advanced diagnostics remain out of reach: disease advances in silence, and the operating room becomes, by default, the first line of detection. It is a reminder that the tools a health system lacks do not make illness disappear — they only delay the moment of reckoning.
Nearly half of prostate surgeries in Burundi reveal incidental cancer, mostly aggressive
Patients with incidental high-grade prostate cancer may face delayed treatment and worse outcomes due to late detection during surgery for benign disease.
Cancer discovered not through screening, but only after tissue came back from pathology
Mark
Why would cancer hide so effectively in men who had standard preoperative screening?
Mimi
Because the screening tools available—PSA blood tests and digital rectal exams—are imperfect. They catch some cancers, but many grow in the transition zone of the prostate, the part that gets removed during surgery for benign disease. A biopsy might sample the peripheral zone where most cancers live, but it misses the transition zone entirely.
Mark
So these men were essentially unlucky. They had cancer in the wrong part of the prostate to be found by the usual methods.
Mimi
Partly, yes. But there's also a resource question. In developed countries, men with elevated PSA or suspicious findings get MRI scans and targeted biopsies. That catches cancers earlier, before surgery. Here, those tools don't exist. Surgery becomes the diagnostic moment.
Mark
The aggressive tumors—grade 5—that's the worst kind?
Mimi
Yes. Fifty-six percent of the incidental cancers were grade 5. These are fast-growing, likely to spread. A man comes in thinking he needs help with urination and learns he has advanced cancer that's been growing undetected.
Mark
What happens to them after surgery?
Mimi
The study doesn't say. But the implication is clear: they need immediate treatment—radiation, chemotherapy, possibly more surgery. They've lost time. The cancer had years to progress while they were being treated for something else.
Mark
Could better screening prevent this?
Mimi
In theory, yes. But screening requires infrastructure—imaging machines, trained radiologists, biopsy capacity. Burundi doesn't have that at scale. So the real answer is: make sure every tissue sample gets examined carefully. It's the one diagnostic moment you have.
Mark
Is this a Burundi problem or a global one?
Mimi
It's a resource problem. Wealthy countries saw this decades ago and built screening systems. Poorer countries are still catching cancer the old way—by accident, during surgery for something else.
El Pulso
- Surgeons in Burundi set out to relieve urinary obstruction and instead uncovered cancer in 76 of 156 patients — nearly half — none of whom had been diagnosed beforehand.
- Over half of those cancers were grade 5 tumors, the most dangerous classification, meaning the disease had not merely been missed but had been silently advancing toward its worst form.
- Standard preoperative tools — PSA tests, rectal exams, ultrasound — failed to raise suspicion in the majority of cases, with 57 percent of cancer patients showing PSA levels below the threshold considered alarming.
- The absence of multiparametric MRI and systematic biopsy protocols, standard in wealthier settings, left clinicians navigating by instruments too blunt to catch what was there.
- The study's authors argue that routine histopathological examination of every removed prostate specimen is not optional in resource-limited environments — it may be the only safety net available.
In Bujumbura, Burundi, a year-long examination of men undergoing prostate surgery for what appeared to be benign disease revealed that nearly half harbored undetected cancers — most of them aggressive — discovered only when surgical tissue reached the pathologist. The finding speaks to a quiet crisis in places where advanced diagnostics remain out of reach: disease advances in silence, and the operating room becomes, by default, the first line of detection. It is a reminder that the tools a health system lacks do not make illness disappear — they only delay the moment of reckoning.
In Bujumbura, Burundi, a review of 156 men who underwent prostate surgery at five hospitals over one year produced a striking and troubling finding: 76 of them — 48.72 percent — had prostate cancer that no one had detected before the operation. The diagnosis arrived not through screening or imaging, but only after surgical tissue was examined by a pathologist.
The men, averaging 69 years of age, had come to surgery with the familiar complaints of benign prostate enlargement — difficulty urinating, frequent nighttime trips to the bathroom. Their doctors performed standard preoperative checks, including digital rectal exams, PSA blood tests, and ultrasound. Most exams felt normal. Only 21 patients received a biopsy before surgery, and all returned negative results. The rest entered the operating room with no suspicion of malignancy.
What pathology revealed was sobering. Among the 76 men with incidental cancer, 43 — more than 56 percent — had grade 5 tumors, the most aggressive classification in the urological grading system. Among those who underwent the most common procedure, transurethral resection, cancer appeared in 58 percent of cases. The study also identified an unusually high number of squamous cell carcinomas, a rare prostate cancer type, though the absence of immunohistochemical confirmation left some diagnostic questions open.
The findings illuminate a structural gap. Burundi lacks the advanced imaging — multiparametric MRI chief among them — that allows clinicians in wealthier countries to detect cancer before surgery. Notably, 57 percent of patients with cancer had PSA levels below 4 nanograms per milliliter, the conventional threshold for concern, meaning even that basic tool offered false reassurance. In developed countries, the rise of PSA screening reduced incidental cancer detection rates from as high as 27 percent down to roughly 5 to 9 percent — but that improvement came alongside better medications that reduced the need for surgery in the first place. In Burundi, men still reach the operating room more frequently, and the cancers they carry arrive with them unannounced.
The study's authors conclude that systematic histopathological examination of every prostate specimen removed during surgery is not a refinement but a necessity — particularly where earlier detection methods are unavailable. Without it, clinically significant cancers remain hidden until they have had time to grow, and men who came seeking relief from a benign condition leave carrying a far graver diagnosis.
In Bujumbura, Burundi, surgeons operating on men for what they believed was benign prostate trouble discovered something far more serious in nearly half their patients: cancer. A year-long review of 156 men who underwent prostate surgery at five major hospitals revealed that 76 of them—48.72 percent—had prostate cancer that no one had detected beforehand. The finding arrived not through screening or imaging, but only after the tissue came back from pathology.
The men in the study had an average age of 69 years. Most came to surgery complaining of lower urinary tract symptoms—difficulty urinating, frequent trips to the bathroom—the classic signs of benign prostate enlargement. Their doctors performed the standard preoperative checks: digital rectal exams, blood tests for prostate-specific antigen, and ultrasound. In 86 patients, the rectal exam felt normal. In 41, doctors detected a nodule. Only 21 patients underwent biopsy before surgery, and all those biopsies came back negative. The rest went to the operating room with no suspicion of malignancy.
What the pathologist found when examining the surgical specimens told a different story. Among the 76 men with incidental cancer, the tumors were predominantly aggressive. Using the International Society of Urological Pathology grading system, 43 patients—56.58 percent of those with cancer—had grade 5 tumors, the most dangerous classification. Only nine had grade 1 disease. The pattern held across different surgical approaches. Among the 60 men who underwent transurethral resection of the prostate, the most common procedure, cancer appeared in 35 of them, or 58.33 percent.
The study also identified 25 cases of squamous cell carcinoma, a rarer form. Seventeen were primary tumors arising in the prostate itself, while eight represented spread from bladder cancer. The presence of so many primary squamous cell carcinomas—a type that accounts for less than one percent of prostate cancers in the literature—raised questions about diagnostic accuracy, since the pathologists relied on routine microscopy without immunohistochemical confirmation.
The findings expose a gap in how prostate disease is evaluated in resource-limited settings. Burundi lacks the advanced imaging tools—multiparametric MRI, for instance—that developed countries use to detect cancer before surgery. The men in this study had PSA levels measured and rectal exams performed, but these tools missed the majority of cancers that were later found. Fifty-seven percent of the patients had PSA levels below 4 nanograms per milliliter, the threshold typically considered normal, yet cancer was present in many of them.
The study's authors note that the introduction of PSA screening decades ago actually reduced the rate of incidental prostate cancer detection in developed countries, from rates as high as 27 percent down to around 5 to 9 percent. But that decline came with a trade-off: fewer men underwent surgery for benign disease in the first place, as medical treatments improved. In Burundi, where access to medications and advanced diagnostics remains limited, men still undergo surgery more frequently, and the cancers they harbor go undetected until the pathologist examines what was removed.
The implications are sobering. Men who came to surgery expecting treatment for urinary obstruction left with a diagnosis of advanced cancer that had already progressed while they waited. The study underscores why systematic examination of all tissue removed during prostate surgery matters, particularly where screening infrastructure is weak. Without it, clinically significant cancers remain hidden until they have had time to grow and spread. The authors conclude that routine histopathological evaluation of every prostate specimen is not a luxury but a necessity—especially in places where patients cannot rely on earlier detection methods to catch disease before it reaches the operating room.
Citas Notables
Routine histopathological examination of all prostate surgical specimens remains essential, particularly in resource-limited settings, to avoid missing clinically significant incidental cancers.— Study authors, conclusion
The predominance of high-grade tumors highlights the importance of systematic histopathological evaluation of all prostate surgical specimens, particularly in resource-limited settings where access to advanced diagnostic tools remains limited.— Study authors, abstract
Quieres la nota completa?
Lee el original en SCIRP Open Access ↗
Health & Medicine